A subset of human immunodeficiency virus type 1 long-term non-progressors is characterized by the unique presence of ancestral sequences in the viral population.
Within human immunodeficiency virus type 1 (HIV-1)-infected patients, there are those who have been infected for more than 10 years with a CD4+ cell count of >500 cells microl(-1) and who remain asymptomatic without antiretroviral therapy; these patients are designated long-term non-progressors (LTNPs). In a set of 16 LTNPs, viral dating, DNA viral load, quasispecies heterogeneity and antibody (Ab) titres against gp160 and beta2 microglobulin (beta2m) were determined. Plasma viral RNA and CD4+ and CD8+ T-cell numbers were estimated in more than three samples per patient. Host genetic characteristics, such as Delta32-CCR5 genotype and human leukocyte antigen (HLA) genotype and supertypes, and clinical-epidemiological factors were evaluated. Dating of global populations and of DNA and RNA viral quasispecies identified two subsets of patients: one displaying only ancestral sequences and the other displaying predominantly modern sequences. The ancestral patients displayed a significant reduction in RNA and DNA viral loads, quasispecies heterogeneity, CD8+ cell number, anti-gp160 Ab titres and beta2m level, and they were also associated with better use of safe-sex practices and higher presence of the HLA sB58 supertype than the modern subset. Viral dating has therefore permitted the segregation of LTNPs into two subsets that show very different virological, immunological, host and clinical-epidemiological characteristics. Moreover, whereas the modern subset displayed low levels of virus replication, the ancestral group displayed not only a very limited virus replication, often to undetectable levels, but also very slow or arrested viral evolution, maintaining the close relationship of the viral population to the transmitted virus.
Bello
Gonzalo
G
Centro Nacional de Microbiología, Instituto de Salud Carlos III, Majadahonda, 28220 Madrid, Spain.
Casado
Concepción
C
Centro Nacional de Microbiología, Instituto de Salud Carlos III, Majadahonda, 28220 Madrid, Spain.
Sandonis
Virginia
V
Centro Nacional de Microbiología, Instituto de Salud Carlos III, Majadahonda, 28220 Madrid, Spain.
Alonso-Nieto
Manuela
M
Histocompatibilidad, Centro de Transfusión de la Comunidad de Madrid, 28032 Madrid, Spain.
Vicario
José Luis
JL
Histocompatibilidad, Centro de Transfusión de la Comunidad de Madrid, 28032 Madrid, Spain.
García
Soledad
S
Centro Sanitario Sandoval, IMSALUD, 28010 Madrid, Spain.
Hernando
Victoria
V
Centro Sanitario Sandoval, IMSALUD, 28010 Madrid, Spain.
Rodríguez
Carmen
C
Centro Sanitario Sandoval, IMSALUD, 28010 Madrid, Spain.
Romero
Jorge Del
JD
Centro Sanitario Sandoval, IMSALUD, 28010 Madrid, Spain.
López-Galíndez
Cecilio
C
Centro Nacional de Microbiología, Instituto de Salud Carlos III, Majadahonda, 28220 Madrid, Spain.
D016516:CD4-CD8 Ratio; D004279:DNA, Viral / Q000032:analysis; D005838:Genotype; D015483:HIV Antibodies / Q000097:blood; D019302:HIV Envelope Protein gp160 / Q000276:immunology; D015658:HIV Infections / Q000453:epidemiology / Q000235:genetics / Q000821:virology*; D020276:HIV Long-Term Survivors; D015497:HIV-1 / Q000235:genetics*; D006680:HLA Antigens / Q000235:genetics; D006801:Humans; D010802:Phylogeny; D012367:RNA, Viral / Q000032:analysis; D019713:Receptors, CCR5 / Q000235:genetics; D021841:Safe Sex; D013030:Spain / Q000453:epidemiology; D019562:Viral Load; D001613:beta 2-Microglobulin / Q000276:immunology
D004279:DNA, Viral; D015483:HIV Antibodies; D019302:HIV Envelope Protein gp160; D006680:HLA Antigens; D012367:RNA, Viral; D019713:Receptors, CCR5; D001613:beta 2-Microglobulin